Sharespot RSS feed

HIV Telehealth Education for Providers in Rural and Medically Underserved Areas of Kentucky

Publish Date: 
Tuesday, May 26, 2015

Rural Kentucky often evokes images of poverty and despair. While reaching out to providers in this area, SCAETTC (Southern Central AIDS Education Telehealth Training Center) can attest that poverty and limited resources are real and must be addressed.  Disparities within this area remain unnoticed and the majority of Kentucky’s Appalachian counties are designated as medically underserved.

Author: 

Adult and Adolescent Guidelines: Major Changes

Publish Date: 
Tuesday, April 28, 2015

The U.S. Department of Health and Human Services has released new treatment guidelines for adults and adolescents, and these contain some important changes. Key among these is a major shakeup in the "Recommended Regimen Options" for initial therapy. 

Author: 

Some Thoughts on Building Capacity for the AETC Practice Transformation Projects

Publish Date: 
Tuesday, April 28, 2015

While there are many unknowns about exactly what the AETCs will look like with the start of the new grant cycle later this year, one thing we do know is that Practice Transformation (PT) and Practice Facilitation will be a part of the work.  In fact about 40% of AETC resources will be devoted to the PT projects.  This is a new direction for the AETC and there are many unanswered questions about how this work will evolve.  As we move toward taking on this challenge some obvious questions arise: Why is Practice Transformation important?  What is PT and how can we learn about it?  How is PF di

Author: 

Once-Daily Dosing of Lamivudine and Abacavir for Pediatric Patients

Publish Date: 
Monday, April 20, 2015

The U.S. Food and Drug Administration has approved once-daily dosing recommendations for lamivudine and abacavir for HIV-infected children. Previously, these NRTIs were approved only for twice-daily dosing in children. The dosing revisions apply to both the oral solution and the tablet formulations of these drugs.

Author: 

Testosterone Therapy in HIV-Infected Men: Suboptimal Testing for Diagnosis and Monitoring

Publish Date: 
Monday, April 20, 2015

Very few data are available to gauge the possible benefits and adverse effects of long-term testosterone supplementation in HIV-infected men. Despite this, and despite concerns about possible risks of testosterone supplementation (eg, cardiovascular events, prostate cancer), testosterone continues to be widely prescribed for both HIV-infected and HIV-uninfected men in the United States.

Author: 

Using Fellowships to Impact HIV Workforce Deficits

Publish Date: 
Wednesday, April 1, 2015

A critical shortage of practitioners who treat HIV/AIDS patients in the United States is on the horizon, according to research by the American Academy of HIV Medicine (AAHIVM), which warns that more than 32 percent of today’s HIV clinicians will stop providing that care over the next 10 years. Nearly one-third of today’s workforce will retire leaving a shortage unless new practitioners can be encouraged to replace them.

Two New Boosted-PI Coformulations

Publish Date: 
Tuesday, March 17, 2015
The coformulations will make it possible to treat patients with more compact PI-based regimens, (and single-pill combinations containing these boosted PIs + 2 NRTIs may be available in the future). Adverse effects to cobicistat appear to be very similar to those associated with ritonavir, and drug-drug interactions also are about the same.
Author: 

Drug-Drug Interactions: Tenofovir with Boosted PI + Ledipasvir

Publish Date: 
Tuesday, March 17, 2015

It has been reported that the hepatitis C combination medication ledipasvir/sofosbuvir (LDV/SOF, Harvoni), and in particular the ledipasvir component, may increase tenofovir levels in the body. It also is known from previous investigations that ritonavir-boosted protease inhibitors (PIs) increase serum tenofovir concentrations. Thus, there has been a concern that coadministration of tenofovir with both ledipasvir and a boosted PI may increase the risk of renal toxicity.

Author: 

Pages

Subscribe to Sharespot RSS feed